drugset / Trial / NCT00872625

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

NCT00872625

Phase 1 Completed 26 enrolled Centre Antoine Lacassagne
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in higher doses over a shorter period of time may kill more tumor cells and have fewer side effects. Drugs used in chemotherapy, such as docetaxel, epirubicin, cyclophosphamide, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of radiation therapy when given together with docetaxel followed by standard therapy in treating women with breast cancer.

Timeline

Start
2007-04
Primary completion
2009-04
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule Intravenous
Background Cyclophosphamide Other / unclassified Intravenous
Background Epirubicin Small molecule Intravenous
Background fluorouracil Small molecule Intravenous